
The U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) in response to Spero Therapeutics ‘ (NASDAQ:SPRO) New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for the treatment of adult patients with complicated urinary tract infection (cUTI), including pyelonephritis.
The New Drug Application (NDA) was supported by the clinical data readout from the Phase 3 study investigating tebipenem HBr.